NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.8175
-0.0225 (-2.68%)
At close: Dec 24, 2025, 1:00 PM
0.8427
+0.0252 (3.08%)
After-hours: Dec 24, 2025, 2:59 PM EST
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$509,294
Market Cap
20.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NRSN News
- 3 days ago - NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - PRNewsWire
- 21 days ago - NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - PRNewsWire
- 4 weeks ago - NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - PRNewsWire
- 7 weeks ago - NeuroSense to Host Investor Webinar on December 8, 2025 - PRNewsWire
- 2 months ago - NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers - PRNewsWire
- 3 months ago - NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons - PRNewsWire
- 4 months ago - NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price - PRNewsWire
- 5 months ago - NeuroSense Provides Business Update and Progress for the First Half of 2025 - PRNewsWire